Track topics on Twitter Track topics that are important to you
Frontier Pharma: Dermatology Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and FirstinClass Innovation
Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare autoimmune disorders such as scleroderma, to very common conditions such as acne vulgaris and atopic dermatitis. For the past decade the majority of the therapeutic dermatology market has been saturated and highly genericized, and strongly dominated by small molecules. There is a significant unmet need for more efficacious and safer treatment options, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues with the longterm use of many available treatments.
Although the scope of dermatological disorders is diverse in terms of severity, clinical presentation, and key patient demographics, there is a degree of crossover between many indications in terms of their underlying pathophysiology. Increased inflammation and aberrant immune response resulting in skin barrier dysfunction are commonly shared causes. Infections and dysfunctions in wound healing are also common causes of dermatological diseases.
Scientific advancements over the course of recent decades have revealed a broad range of novel potential molecular targets, enabling the advancement of a previously stagnant field. This is reflected in the high number of products being developed, with 961 pipeline products currently in the dermatology therapy area pipeline.
Analysis indicates that the current pipeline is following a trend of focusing on innovative biologic therapies, following the clinical and commercial success of such therapies in the treatment of psoriasis. There are various biologics in the pipeline for major skin disorders including atopic dermatitis, acne vulgaris and rosacea for which there is a significant unmet need in patients with moderatetosevere conditions.
Moreover, there is a considerable degree of innovation present in the therapy area, as there are a total of 197 firstinclass pipeline products in development for dermatological indications, representing 32% of the 617 pipeline products for which there is a disclosed molecular target. Many of these appear promising in terms of safety and efficacy, and carry a significant potential to strengthen the treatment landscape for various dermatological conditions.
With 961 products in active development, the pipeline is considerably large. How will pipeline innovation affect the future dermatology market?
There are 197 firstinclass products in the dermatology pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
The majority of firstinclass products are in development for indications involving inflammation. Which firstinclass targets are most promising, and how does the ratio of firstinclass targets to firstinclass products differ by stage of development and molecular target class?
A significant number of firstinclass products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which firstinclass programs have not yet been involved in a licensing or codevelopment deal?
Reasons to buy
Understand the current clinical and commercial landscape. The report includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
Visualize the composition of the dermatology market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating dermatological diseases, including rare conditions.
Assess the therapeutic potential of firstinclass targets. Using proprietary matrices, firstinclass products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: inflammatory diseases, infectious diseases, and wounds/scars. Promising targets have been reviewed in greater detail.
Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and codevelopment deals, and producing a list of firstinclass therapies with no prior involvement in licensing or codevelopment deals.
Original Article: Frontier Pharma: Dermatology Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and FirstinClass Innovation [Report Updated: 01062017] Prices from USD $6995NEXT ARTICLE
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...
Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...